{"id":"cbl-514","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperphosphatemia"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL3656216","moleculeType":"Small molecule","molecularWeight":"397.56"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CBL-514 targets FGFR pathways that are dysregulated in various cancers and fibrotic diseases. By inhibiting FGFR signaling, the drug aims to suppress tumor growth and reduce pathological fibrosis. The selective nature of the inhibitor is designed to minimize off-target effects while maintaining efficacy against FGFR-dependent malignancies.","oneSentence":"CBL-514 is a selective inhibitor of fibroblast growth factor receptor (FGFR) signaling.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:05:00.903Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"FGFR-driven solid tumors (specific indications in phase 3 development)"}]},"trialDetails":[{"nctId":"NCT07140939","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat","status":"NOT_YET_RECRUITING","sponsor":"Caliway Biopharmaceuticals Co., Ltd.","startDate":"2025-09","conditions":"Subcutaneous Fat","enrollment":300},{"nctId":"NCT06303570","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of CBL-514 Compared to Placebo in Participants With Dercum's Disease Lipomas","status":"RECRUITING","sponsor":"Caliway Biopharmaceuticals Co., Ltd.","startDate":"2024-11-27","conditions":"Dercum's Disease","enrollment":20},{"nctId":"NCT06005441","phase":"PHASE2","title":"A Phase 2b Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat.","status":"COMPLETED","sponsor":"Caliway Biopharmaceuticals Co., Ltd.","startDate":"2023-11-10","conditions":"Subcutaneous Fat","enrollment":173},{"nctId":"NCT04575467","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1)","status":"COMPLETED","sponsor":"Caliway Biopharmaceuticals Co., Ltd.","startDate":"2020-12-09","conditions":"Subcutaneous Fat","enrollment":25},{"nctId":"NCT05736107","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat","status":"COMPLETED","sponsor":"Caliway Biopharmaceuticals Co., Ltd.","startDate":"2023-05-30","conditions":"Subcutaneous Fat","enrollment":107},{"nctId":"NCT05836779","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 2)","status":"COMPLETED","sponsor":"Caliway Biopharmaceuticals Co., Ltd.","startDate":"2023-05-10","conditions":"Cellulite","enrollment":23},{"nctId":"NCT05632926","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 1)","status":"COMPLETED","sponsor":"Caliway Biopharmaceuticals Co., Ltd.","startDate":"2023-01-09","conditions":"Cellulite","enrollment":12},{"nctId":"NCT04897412","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 2)","status":"COMPLETED","sponsor":"Caliway Biopharmaceuticals Co., Ltd.","startDate":"2022-02-14","conditions":"Subcutaneous Fat","enrollment":75},{"nctId":"NCT05387733","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With Dercum's Disease Lipomas","status":"COMPLETED","sponsor":"Caliway Biopharmaceuticals Co., Ltd.","startDate":"2022-10-03","conditions":"Dercum's Disease","enrollment":12},{"nctId":"NCT05234736","phase":"PHASE2","title":"A Study to Evaluate the Pharmacokinetic Profile of CBL-514 Injection in Healthy Volunteers","status":"COMPLETED","sponsor":"Caliway Biopharmaceuticals Co., Ltd.","startDate":"2022-02-11","conditions":"Subcutaneous Fat","enrollment":10},{"nctId":"NCT04698642","phase":"PHASE2","title":"A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of CBL-514 Injection for Reducing Convexity or Fullness of Abdominal Subcutaneous Fat","status":"COMPLETED","sponsor":"Caliway Biopharmaceuticals Co., Ltd.","startDate":"2020-02-03","conditions":"Subcutaneous Fat","enrollment":43},{"nctId":"NCT04699669","phase":"PHASE1","title":"A Phase 1 Study to Evaluate the Safety and Tolerability of CBL-514 Injection on Convexity or Fullness of Abdominal Subcutaneous Fat in Healthy Volunteers","status":"COMPLETED","sponsor":"Caliway Biopharmaceuticals Co., Ltd.","startDate":"2018-11-27","conditions":"Subcutaneous Fat","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"CBL-514","genericName":"CBL-514","companyName":"Caliway Biopharmaceuticals Co., Ltd.","companyId":"caliway-biopharmaceuticals-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CBL-514 is a selective inhibitor of fibroblast growth factor receptor (FGFR) signaling. Used for FGFR-driven solid tumors (specific indications in phase 3 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}